TD Cowen Boosts Danaher (NYSE:DHR) Price Target to $310.00

Danaher (NYSE:DHR) had its price target increased by TD Cowen from $290.00 to $310.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the conglomerate’s stock.

Several other equities research analysts also recently commented on DHR. Robert W. Baird boosted their target price on Danaher from $259.00 to $271.00 and gave the stock an outperform rating in a report on Wednesday, April 24th. HSBC raised Danaher from a hold rating to a buy rating and boosted their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Citigroup boosted their target price on Danaher from $280.00 to $290.00 and gave the stock a buy rating in a report on Wednesday, April 24th. The Goldman Sachs Group boosted their target price on Danaher from $225.00 to $250.00 and gave the stock a neutral rating in a report on Wednesday. Finally, Jefferies Financial Group assumed coverage on Danaher in a report on Monday, June 3rd. They issued a buy rating and a $295.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $276.88.

Danaher Price Performance

Shares of DHR stock opened at $273.91 on Wednesday. The stock has a market cap of $197.82 billion, a price-to-earnings ratio of 46.43, a PEG ratio of 4.18 and a beta of 0.83. The business’s fifty day moving average is $255.16 and its 200 day moving average is $249.22. Danaher has a twelve month low of $182.09 and a twelve month high of $277.72. The company has a quick ratio of 1.51, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.05 earnings per share. Research analysts expect that Danaher will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, July 26th. Shareholders of record on Friday, June 28th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date was Friday, June 28th. Danaher’s payout ratio is 18.31%.

Insiders Place Their Bets

In other Danaher news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Danaher news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders sold a total of 84,775 shares of company stock worth $21,802,690 over the last quarter. 11.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Danaher

Several institutional investors have recently made changes to their positions in the business. HB Wealth Management LLC grew its position in shares of Danaher by 17.0% during the second quarter. HB Wealth Management LLC now owns 11,709 shares of the conglomerate’s stock worth $2,926,000 after purchasing an additional 1,705 shares in the last quarter. 1834 Investment Advisors Co. grew its position in shares of Danaher by 17.0% during the second quarter. 1834 Investment Advisors Co. now owns 1,541 shares of the conglomerate’s stock worth $385,000 after purchasing an additional 224 shares in the last quarter. Strategic Blueprint LLC grew its position in shares of Danaher by 10.2% during the second quarter. Strategic Blueprint LLC now owns 10,069 shares of the conglomerate’s stock worth $2,516,000 after purchasing an additional 933 shares in the last quarter. Fort Pitt Capital Group LLC grew its position in shares of Danaher by 4.6% during the second quarter. Fort Pitt Capital Group LLC now owns 230,671 shares of the conglomerate’s stock worth $57,633,000 after purchasing an additional 10,174 shares in the last quarter. Finally, Kintegral Advisory LLC grew its position in shares of Danaher by 452.0% during the second quarter. Kintegral Advisory LLC now owns 26,738 shares of the conglomerate’s stock worth $6,688,000 after purchasing an additional 21,894 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.